← Leaderboards
Xiaomin Fan
Avantgen, Inc.
$10,211,674
Attributed
$11,243,708
Total exposure
18
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,243,708 · 18
By mechanism
R44$3,759,778 · 2
N44$3,751,179 · 3
R43$1,984,187 · 7
N43$1,448,710 · 5
N01$299,854 · 1
Top collaborators
- Lakshmi A Devi3 shared
- Jeffrey Billheimer1 shared
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesAffinityYeastsAntigensLibrariesSpecificityReagentEnzyme-Linked Immunosorbent AssayCellsProductionBinding (Molecular Function)Oryctolagus CuniculusExhibitsProteinsTechnologyMonoclonal AntibodiesLabelLeadBasePlayResponseNovel StrategiesPharmaceutical PreparationsAntibody Affinity
Grant awards (23)
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)$574,272
R44 · FY2025 · CA · contact PI
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)$1,398,552
R44 · FY2024 · CA · contact PI
DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS$592,751
N43 · FY2024 · AI · contact PI
DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS$356,021
N43 · FY2021 · AI · contact PI
Development and validation of anti-canine reagents to enable pre-clinical development of novel therapeutics$1,995,852
N44 · FY2020 · CA · contact PI
IGF::OT::IGF Topic 372 - SBIR Phase I: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics - Moonshot$299,854
N01 · FY2018 · CA · contact PI
Novel approach for developing antibody reagents to probe changes in the synapse p$805,808
R44 · FY2016 · DA · contact PI
Novel approach for developing antibody reagents to probe changes in the synapse p$756,189
R44 · FY2015 · DA · contact PI
Developing a highly specific and sensitive glucagon ELISA kit$224,670
R43 · FY2015 · DK · contact PI
Discovery of novel Alzheimer's Disease-specific antigens/epitopes and their captu$224,528
R43 · FY2014 · AG · contact PI
Novel platform for isolation of rabbit monoclonal antibodies against modified RNA bases$188,104
R43 · FY2014 · DA · contact PI
Novel approach for developing antibody reagents to probe changes in the synapse p$224,957
R44 · FY2013 · DA · contact PI
TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES$199,987
N43 · FY2013 · CA · contact PI
OTHER FUNCTIONS - RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES$990,779
N44 · FY2012 · HL · contact PI
A novel approach for developing GPCR subtype specific antibodies$341,965
R43 · FY2012 · MH · contact PI
TAS::75 0893::TAS RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS$14,548
N44 · FY2012 · DA · contact PI
A novel approach for developing GPCR subtype specific antibodies$349,719
R43 · FY2011 · MH · contact PI
TAS::75 0893::TAS RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS$750,000
N44 · FY2010 · DA · contact PI
Endothelial Lipase: a novel therapeutic target for HDL and atherosclerosis$277,115
R43 · FY2010 · HL · contact PI
TAS::75 0849::TAS DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE$150,000
N43 · FY2010 · CA · contact PI
TAS::75 0872::TAS RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES$149,951
N43 · FY2010 · HL · contact PI
Novel human anti-uPAR antibodies for the treatment of pancreatic cancer$158,025
R43 · FY2009 · CA · contact PI
A novel therapeutic antibody for treatment of ischemic stroke.$220,061
R43 · FY2008 · NS · contact PI